Protalix BioTherapeutics, Inc. (PLX)
ASE – Real vaqt narxi. Valyuta: USD
1.91
-0.03 (-1.55%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.92
+0.01 (0.52%)
Bozordan keyin: May 12, 2026, 5:57 PM EDT
Find any stock by ticker or company name

ASE – Real vaqt narxi. Valyuta: USD
1.91
-0.03 (-1.55%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.92
+0.01 (0.52%)
Bozordan keyin: May 12, 2026, 5:57 PM EDT
Protalix BioTherapeutics, Inc., biotexnologiya kompaniyasi, ProCellEx o'simlik hujayralari asosidagi oqsil ekspressiyasi tizimiga asoslangan rekombinant terapevtik oqsillarni ishlab chiqish, ishlab chiqarish va tijoratlashtirish bilan shug'ullanadi. Kompaniya Gaucher kasalligini davolash uchun Elelyso; va Fabry kasalligini tasdiqlangan tashxisi bo'lgan kattalar bemorlarni davolash uchun Elfabrio taqdim etadi. Shuningdek, podagrani davolash uchun 2-bosqichli sinovlarda bo'lgan o'simlik hujayralarida ifodalangan rekombinant PEGylatlangan Urikaza PRX-115; va neytrofillardan tashkil topgan o'simlik hujayralarida ifodalangan PEGylatlangan rekombinant inson DNaz I mahsuloti nomzodi PRX-119 ni ishlab chiqmoqda. Kompaniya Pfizer; Fundação Oswaldo Cruz; va Chiesi Farmaceutici S.p.A. bilan kelishuvlar va hamkorlikka ega. Protalix BioTherapeutics, Inc. Secarna Pharmaceuticals GmbH & Co KG bilan strategik hamkorlikka ega. Kompaniya shtab-kvartirasi Hackensack. Nyu-Jersi shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. Dror Bashan | President, CEO & Director |
| Mr. Gilad Mamlok | Senior VP, CFO Treasurer & Secretary |
| Mr. Yaron Naos B.Sc., MBA | SVP & COO |
| Ms. Yael Fellous | Vice President of Human Resources |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | DEF 14A | plx-20260625xdef14a.htm |
| 2026-03-18 | 8-K | plx-20260318x8k.htm |
| 2026-03-09 | 8-K | plx-20260309x8k.htm |
| 2026-02-11 | 8-K | plx-20260211x8k.htm |
| 2026-01-30 | 8-K | tm264565d1_8k.htm |
| 2026-01-05 | 8-K | plx-20260105x8k.htm |
| 2025-11-13 | 8-K | plx-20251113x8k.htm |
| 2025-11-03 | 8-K | plx-20251103x8k.htm |
| 2025-10-17 | 8-K | plx-20251017x8k.htm |
| 2025-08-22 | 8-K | tm2524070d1_8k.htm |